表观基因组学与卵巢癌。
Epigenomics and ovarian carcinoma.
机构信息
Department of Otolaryngology & Head & Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA.
出版信息
Biomark Med. 2010 Aug;4(4):543-70. doi: 10.2217/bmm.10.72.
Abstract
Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.
摘要
卵巢癌是妇科癌症死亡的主要原因。现在人们认识到，除了遗传改变外，表观遗传机制，如 DNA 甲基化、组蛋白修饰和核小体重塑，通过调节染色质结构以及基因和 miRNA 表达，在卵巢癌的发生和发展中发挥重要作用。此外，表观遗传改变已被认为是开发用于疾病诊断、预后、治疗预测和监测的新型生物标志物的有用工具。此外，发现新的表观遗传疗法，如 DNA 甲基转移酶抑制剂和组蛋白去乙酰化酶抑制剂，是一种潜在的治疗选择，尤其是与其他药物联合使用时。本文讨论了卵巢癌表观基因组研究的最新进展、卵巢癌表观基因组在开发诊断和预后生物标志物方面的重要性，以及目前用于卵巢癌的表观遗传疗法。
相似文献
1
Epigenomics and ovarian carcinoma.表观基因组学与卵巢癌。
Biomark Med. 2010 Aug;4(4):543-70. doi: 10.2217/bmm.10.72.
2
Targeting the epigenome in ovarian cancer.靶向卵巢癌的表观基因组。
Future Oncol. 2012 Feb;8(2):151-64. doi: 10.2217/fon.11.152.
3
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.上皮性卵巢癌化疗增敏的表观遗传学治疗。
Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.
4
Epigenetic therapy for ovarian cancer: promise and progress.卵巢癌的表观遗传学治疗：前景与进展。
Clin Epigenetics. 2019 Jan 15;11(1):7. doi: 10.1186/s13148-018-0602-0.
5
Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a -Dependent Manner.表观遗传学疗法在卵巢癌中以依赖 - 的方式改变重复元件的表达。
Cancer Res. 2021 Oct 15;81(20):5176-5189. doi: 10.1158/0008-5472.CAN-20-4243. Epub 2021 Aug 25.
6
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.组蛋白去乙酰化酶抑制剂与 EZH2 的催化抑制剂协同作用，在卵巢小细胞癌，血钙过多型中表现出抗肿瘤活性。
Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.
7
Targeting Chromatin Remodeling for Cancer Therapy.靶向染色质重塑治疗癌症。
Curr Mol Pharmacol. 2019;12(3):215-229. doi: 10.2174/1874467212666190215112915.
8
Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.药物-表观基因组学：发现癌症治疗的治疗方法和生物标志物。
Heredity (Edinb). 2010 Jul;105(1):152-60. doi: 10.1038/hdy.2010.42. Epub 2010 Apr 14.
9
Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.利用乳腺癌表观遗传突变可逆性的当前及未来方法。
Breast Cancer Res. 2014 Jul 29;16(4):412. doi: 10.1186/s13058-014-0412-z.
10
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.上皮性卵巢癌化疗耐药的表观遗传机制及治疗靶点
Ann Med. 2015;47(5):359-69. doi: 10.3109/07853890.2015.1043140. Epub 2015 Jul 10.
引用本文的文献
1
Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer.基因甲基化作为卵巢癌潜在的表观遗传标志物
Clin Med Insights Oncol. 2025 Jun 20;19:11795549251340531. doi: 10.1177/11795549251340531. eCollection 2025.
2
Study on the Function and Mechanism of miR-585-3p Inhibiting the Progression of Ovarian Cancer Cells by Targeting FSCN1 to Block the MAPK Signaling Pathway.miR-585-3p 通过靶向 FSCN1 阻断 MAPK 信号通路抑制卵巢癌细胞进展的功能及机制研究。
Anal Cell Pathol (Amst). 2022 May 13;2022:1732365. doi: 10.1155/2022/1732365. eCollection 2022.
3
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.miR-132-3p 在实体瘤发生中的突出作用。
Hum Cell. 2021 Jul;34(4):1051-1065. doi: 10.1007/s13577-021-00544-w. Epub 2021 May 17.
4
miR-4461 Regulates the Proliferation and Metastasis of Ovarian Cancer Cells and Cisplatin Resistance.miR-4461调控卵巢癌细胞的增殖、转移及顺铂耐药性。
Front Oncol. 2021 Mar 9;11:614035. doi: 10.3389/fonc.2021.614035. eCollection 2021.
5
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions.妇科护理最新进展：改善罕见妇科肿瘤诊断与治疗的现代策略——当前挑战与未来方向
Cancers (Basel). 2021 Jan 27;13(3):493. doi: 10.3390/cancers13030493.
6
Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis (Review).长非编码 RNA 及其相关表观遗传机制在肝纤维化中的作用（综述）。
Int J Mol Med. 2021 Mar;47(3). doi: 10.3892/ijmm.2021.4856. Epub 2021 Jan 26.
7
Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma.患卵巢癌情况不一致的同卵双胞胎的全基因组甲基化图谱。
Oncol Lett. 2020 Dec;20(6):357. doi: 10.3892/ol.2020.12221. Epub 2020 Oct 14.
8
LncRNA MALAT1 Regulates the Progression and Cisplatin Resistance of Ovarian Cancer Cells via Modulating miR-1271-5p/E2F5 Axis.长链非编码RNA MALAT1通过调控miR-1271-5p/E2F5轴调节卵巢癌细胞的进展和顺铂耐药性。
Cancer Manag Res. 2020 Oct 12;12:9999-10010. doi: 10.2147/CMAR.S261979. eCollection 2020.
9
Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.长链非编码 RNA PTPRG-AS1 通过诱饵 microRNA-545-3p 促进上皮性卵巢癌细胞的肿瘤发生，并因此增强 HDAC4 表达。
J Ovarian Res. 2020 Oct 24;13(1):127. doi: 10.1186/s13048-020-00723-7.
10
Long non-coding RNA THOR promotes ovarian Cancer cells progression via IL-6/STAT3 pathway.长非编码 RNA THOR 通过 IL-6/STAT3 通路促进卵巢癌细胞的进展。
J Ovarian Res. 2020 Jun 17;13(1):72. doi: 10.1186/s13048-020-00672-1.
本文引用的文献
1
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
2
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip.基于 Illumina Infinium HumanMethylation27 BeadChip 的存档福尔马林固定石蜡包埋组织的全基因组 DNA 甲基化分析。
Methods. 2010 Nov;52(3):248-54. doi: 10.1016/j.ymeth.2010.04.012. Epub 2010 Apr 29.
3
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.鉴定出一种 CpG 岛甲基化表型，它定义了神经胶质瘤的一个独特亚群。
Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15.
4
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.临床试验中的新型组蛋白去乙酰化酶抑制剂作为抗癌药物。
J Hematol Oncol. 2010 Feb 4;3:5. doi: 10.1186/1756-8722-3-5.
5
Methylation analysis by DNA immunoprecipitation.通过 DNA 免疫沉淀进行甲基化分析。
J Cell Physiol. 2010 Mar;222(3):522-31. doi: 10.1002/jcp.22009.
6
Solving the Dnmt2 enigma.解开Dnmt2之谜。
Chromosoma. 2010 Feb;119(1):35-40. doi: 10.1007/s00412-009-0240-6.
7
DNA methylation analysis in liquid-based cytology for cervical cancer screening.用于宫颈癌筛查的液基细胞学中的DNA甲基化分析。
Int J Cancer. 2009 Dec 15;125(12):2995-3002. doi: 10.1002/ijc.24745.
8
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.DNA甲基化和组蛋白乙酰化的联合抑制增强了体内基因的重新表达和药物敏感性。
Br J Cancer. 2009 Mar 10;100(5):758-63. doi: 10.1038/sj.bjc.6604932.
9
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.与卵巢癌化疗反应相关的微小RNA及其靶信使核糖核酸
Gynecol Oncol. 2009 May;113(2):249-55. doi: 10.1016/j.ygyno.2009.01.014. Epub 2009 Feb 23.
10
The promises and pitfalls of epigenetic therapies in solid tumours.实体瘤表观遗传疗法的前景与陷阱
Eur J Cancer. 2009 May;45(7):1129-1136. doi: 10.1016/j.ejca.2009.01.003. Epub 2009 Feb 11.
Zotero 插件